2024-02-262024-02-262008-07Ersoy, C. vd. (2008)" The effect of metformin treatment on VEGF and PAI-1 Levels in obese type 2 diabetic patients". Diabetes Research and Clinical Practice, 81(1), 56-60.0168-82271872-8227https://doi.org/10.1016/j.diabres.2008.02.006https://www.sciencedirect.com/science/article/pii/S0168822708000879https://hdl.handle.net/11452/39968The aim of the study was to evaluate the effect of metformin on markers of endothelial function, vascular inflammation and factors of thrombosis in obese type 2 diabetic patients. Twenty-four type 2 diabetic patients (15 female, 9 male) previously under medical nutrition treatment (MNT) + regular exercise programme (REP) without chronic micro or macrovascular complications with the mean age of 50.5 +/- 1.5 years, diabetes duration of 17.9 +/- 6.3 months and body mass index (BMI) of 31.7 +/- 0.8 kg/m(2) were enrolled in the study. In the first 4 weeks, all the patients continued MNT + REP. In the following 12 weeks, metformin (mean daily dosage of 1381 +/- 85 mg) was added. After the first period with MNT + REP, BMI, waist circumference, fat percentage, blood pressure and HDL cholesterol decreased significantly. After metformin addition, there was a significant decrement in BMI, waist circumference, fat percentage, fasting and postprandial. plasma glucose, hemoglobin A1C, plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor (VEGF) and increment in P cell reserve values of the patients. Our results indicated that, metformin addition had beneficial effect on VEGF and PAI-1 levels in obese type 2 diabetic patients under MNT + REP, independent from its' favourable effects on BMI and glycemic control.eninfo:eu-repo/semantics/closedAccessMetforminObesityPAI-1Type 2 diabetes mellitusEndocrinology & MetabolismVEGFEndothelial growth-factorC-reactive proteinPlasminogen-activator inhibitor-1Cardiovascular risk-factorsGlucagon-like peptide-1Insulin resistanceCirculating levelsTerm treatmentMellitusMarkersAdultAgedBlood glucoseBody mass indexDiabetes mellitus, type 2ExerciseFemaleHumansHypoglycemic agentsLipidsMaleMatrix metalloproteinase 9MetforminMiddle agedObesityPlasminogen activator inhibitor 1Prospective studiesVascular endothelial growth factor aWaist-hip ratioArticle0002575670000102-s2.0-44649103918566081118358555Endocrinology & metabolismDiabetes Mellitus; Biguanide Derivative; Cancer RiskGliforGlucoseHemoglobin A1cHigh density lipoprotein cholesterolMetforminPlasminogen activator inhibitor 1VasculotropinAdultArticleBlood pressureBody fatBody massClinical articleClinical trialDiabetic patientDiet restrictionDisease durationFemaleGlucose blood levelGlycemic controlHumanMaleNon insulin dependent diabetes mellitusObesityPancreas islet beta cellPostprandial stateThrombosisTreatment durationVascular endotheliumVasculitisWaist circumference